Quarterly Result4 Feb 2026, 12:09 pm
Lincoln Pharmaceuticals to Approve Q3 and Nine Months Results on Feb 12, 2026
AI Summary
Lincoln Pharmaceuticals Ltd has announced a board meeting scheduled for February 12, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter and nine months ended on December 31, 2025. The meeting will be held at the company's registered office. In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for securities of the company has been closed from January 01, 2026, and will reopen after the expiry of 48 hours from the time the results become generally available.
Key Highlights
- Lincoln Pharmaceuticals Ltd has scheduled a board meeting on February 12, 2026, to approve the unaudited financial results for Q3 and nine months ended on December 31, 2025.
- The trading window for securities of the company has been closed from January 01, 2026, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.
- The trading window will reopen after the expiry of 48 hours from the time the results become generally available.
Price Impact
More from LINCOPH